Sonlicromanol
AssetAlso KH176, KH176-203, KH176-301
Redox-modulating small molecule targeting ROS and maintaining cellular redox balance
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Oxidative stress and ROS signalling
- 11
- Indications
- 4
- Trials
- 1
- Developer
Indications
11Maternally inherited diabetes and deafness
Phase 3, Recruiting, NCT06451757, clinicaltrials.gov, 7 Oct 2026
Mitochondrial diseases
Phase 3, Recruiting, NCT06451757, clinicaltrials.gov, 7 Oct 2026
Mitochondrial DNA tRNALeu(UUR) m.3243A<G mutation
Phase 3, Recruiting, NCT06451757, clinicaltrials.gov, 7 Oct 2026
8 more
In the full profile
- Targets and what it contains5
- Owner and partners5
- Trials4
- Evidence for its targets3
- Competitors2
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026, 5 sources